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Abstract: Vertebrate hematopoiesis is a complex physiological process that is tightly regulated by
intracellular signaling and extracellular microenvironment. In recent decades, breakthroughs in
lineage-tracing technologies and lipidomics have revealed the existence of numerous lipid molecules
in hematopoietic microenvironment. Lysophosphatidic acid (LPA), a bioactive phospholipid molecule,
is one of the identified lipids that participates in hematopoiesis. LPA exhibits various physiological
functions through activation of G-protein-coupled receptors. The functions of these LPARs have
been widely studied in stem cells, while the roles of LPARs in hematopoietic stem cells have rarely
been examined. Nonetheless, mounting evidence supports the importance of the LPA-LPAR axis in
hematopoiesis. In this article, we have reviewed regulation of hematopoiesis in general and focused
on the microenvironmental and intracellular effects of the LPA in hematopoiesis. Discoveries in these
areas may be beneficial to our understanding of blood-related disorders, especially in the context of
prevention and therapy for anemia.
Keywords: lysophosphatidic acid; lysophosphatidic acid receptors; hematopoiesis; microenvironment;
transcription factor networks; anemia
1. Introduction
Hematopoiesis, a developmental process that gives rise to all cellular components of blood, is
highly complicated and regulated by numerous factors in hematopoietic organs, including the bone
marrow and spleen in adults as well as yolk sac and liver during vertebrate development. In adult
vertebrates, hematopoietic stem cells (HSC) undergo a process of proliferation and terminal specification
to generate all types of mature blood cells [1,2]. However, during embryonic hematopoiesis, blood
cells are generated from non-hematopoietic sources. In vertebrates, hematopoiesis during embryonic
development occurs in two waves: first, the short-lived “primitive wave” is characterized by the
generation of primitive erythrocytes with embryonic globin expression, which are responsible for
rapidly delivering oxygen to the entire embryo [3,4]. Subsequently, the “definitive wave” generates
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long-term hematopoietic stem cells (LH-HSCs), which can differentiate into multiple lineages of blood
cells [5]. However, the cell populations from which the primitive and definitive waves originate
remain to be definitely identified. Demonstrated through lineage tracing and time-lapse imaging,
hematopoietic progenitors in the definitive wave are considered to be generated from endothelial
cells [6,7]. This specialized cell population, which is termed the “hemogenic endothelium” (HE),
gives rise to blood precursor cells through a process called endothelial-to-hematopoietic transition [8].
However, recent studies have supported the hypothesis that primitive hematopoiesis originates from
precursors cells expressing endothelial markers, such as CD31 and FLK1 [9–11]. These precursor cells,
which are neither a component of the mesoderm nor the HE, are termed “hemogenic angioblasts” [5].
Taken together, these findings make it clear that specific endothelial cells give rise to all blood cells,
both primitive and definitive, through endothelial-to-hematopoietic transition during early embryonic
development. However, how each endothelial cell is fated to generate a specific subset of blood cells
remains elusive. It is important to clarify the regulatory mechanisms governing this specification, such
as potential transcriptional regulation or microenvironmental influence.
Lysophosphatidic acid (LPA) is a small, bioactive glycerophospholipid that is derived from
cell membrane phospholipids through autotaxin (ATX) metabolism [12]. It is expressed at low
concentrations in all eukaryotic tissue types and at high concentrations in biological fluids,
especially the serum and plasma [13]. LPA exhibits its various functions through the activation
of multiple transmembrane LPA receptors (termed LPA1–6). All LPA receptors (LPARs) belong to the
G-protein-coupled receptor (GPCR) family. GPCRs are localized on the cell surface, contain seven
transmembrane regions, and mediate between extracellular cues and signal transduction through
the recruitment of G-proteins. By activating different Gα subunits, LPA initiates its various cellular
functions [12,14]. Through these activation mechanisms, LPA is involved in important functions in
mediating cancer progression [15,16]. In recent years, LPA has also been reported to be involved in stem
cell differentiation [17]. For example, LPARs LPA1–3 have been identified in mouse embryonic stem
cells (ESCs) [18]. Moreover, LPA has been suggested to regulate pluripotency in human mesenchymal
stem cells (MSCs) through the transcriptional co-factors YAP and TAZ [19,20]. Activation of LPA1
stimulated the downstream MEF/ROCK to regulate the hippo signaling in MSC cells. On the other
hand, both LPA and ATX have been identified in the bone marrow, indicating that the ATX-LPA axis is
active in this organ, where they may play important roles in hematopoiesis [21]. Remarkably, an LPAR
agonist has been shown to promote terminal myeloid lineage differentiation of HSCs [22–25]. Hence, it
has become clear that LPA and its receptor are pivotal regulators in hematopoiesis. Thus, in this article,
we review the microenvironmental and intracellular effects of LPA during hematopoiesis and myeloid
differentiation in particular.
2. Signaling Pathways of LPA and Its Receptors
2.1. LPA Generation
LPA is one of the most important bioactive lipids in vertebrates. It is composed of a long fatty
acyl chain, a glycerol backbone, and a polar phosphate head group [26]. This growth factor is generated
from both extracellular and intracellular metabolism. Lysophospholipid, which is catalyzed by ATX,
is the major source of the extracellular LPA circulating in biological fluids [27–29] (Figure 1). Interestingly,
expression of ATX has been identified in the bone marrow [21]. Furthermore, ATX is copiously
expressed in CD34+ HSCs and FLT3-ITD+ acute myeloid leukemia (AML) cells. Overexpression of
ATX significantly promotes T cell migration and proliferation in these cells [30]. Moreover, conditional
overexpression of ATX promotes the differentiation of monocytes into macrophages in mice [31].
ATX is also involved in the regulation of the pluripotency transcriptional program, which is mediated
by leukemia inhibitory factor (LIF) and bone morphogenetic proteins (BMP) in HSCs [32]. On the other
hand, intracellular LPA is synthesized by three enzymes localized in the endoplasmic reticulum (ER)
or the mitochondrial membrane: glycerophosphate acyltransferase (GPAT), phospholipase A (PLA),
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and acylglycerol kinase (AGK) [33–35]. Previous studies suggested that PLA2 activity is regulated
by cytokines including IL-1, GM-CSF, and TNFα. The PLA2-dependent MAP kinase/ERK activation
might be involved in hematopoiesis regulation [36,37]. These results suggested that both intracellular
and extracellular LPA metabolism pathways participate in blood cell differentiation. On the other
hand, LPA is substantially degraded by lipid phosphate phosphatase (LPP), a Mg2+-independent
enzyme that is abundantly expressed on the surface of endothelial cells [38]. Evseenko et al. reported
the expression of LPP in the murine bone marrow [21]. LPP may therefore participated as a regulator
of LPA signaling in the bone marrow. Taken together, the identification of the LPA-generation and
LPA-degradation enzymes in the hematopoietic microenvironment suggests the significance of the
ATX-LPA axis in hematopoiesis.
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gene-1 (vzg-1), which is further reported as homolog of murine edg-2. Overexpression of edg-2 in 
neocortical cells promoted the LPA-dependent cell-shape change, which suggested that LPA is the 
ligand of this receptor [42]. LPA1 and LPA2 are widely expressed in most tissues and interact with 
Gi/o, Gq/11, G12/13, or Gs upon activation [43]. Activated G proteins recruit downstream secondary 
messengers, such as MAP kinase, Akt, Rho, and PI3 kinase pathways, which promote cell 
proliferation and cell migration [2]. LPA3 couples with Gq/11 and Gi/o to regulate PLC activation and 
Ca2+ mobilization [43]. P2Y receptors belong to purinergic receptor family, which is demonstrated as 
a key regulators in nervous system [44]. LPA4 is expressed specifically in the pancreas, ovaries, and 
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LPA5, which is expressed at low levels in multiple tissues and is highly expressed in kidney, interacts 
with Gq/11 and G12/13 to increase intracellular cAMP levels [46]. LPA6, which has been reported to 
participate in hair follicle development [47], is the most recently defined member of the LPAR family. 
The specific functions of each receptor have been elucidated in studies using LPA receptor gene-
knockout mice. LPA1-deficient mice exhibited reduced suckling, which was attributed to olfactory 
defects, and developmental abnormalities in the neurological system, whereas LPA2 knockout 
animals had no obvious phenotype [48]. In addition, LPA3-knockout mice exhibited delayed uterine 
implantation, altered embryo spacing, and reduced litter sizes [49]. No noticeable phenotype was 
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2.2. LPA Receptors
G-protein-coupled LPARs are located on the cell membrane and contain seven transmembrane
domains. Upon activation by extracellular LPA, these receptors induce downstream signal transduction
to regulate various physiological functions [39]. To date, at least six membrane-bound LPARs have been
identified (Figure 2); LPA1–3 were originally classified as members of the endothelial differentiation
gene (EDG) family and share similar structures [14,40], whereas LPA4–6 belong to the P2Y receptor
family [39,41]. Chun and his colleagues firstly cloned the cDNA of ventricular zone gene-1 (vzg-1),
which is further reported as homolog of murine edg-2. Overexpression of edg-2 in neocortical cells
promoted the LPA-dependent cell-shape change, which suggested that LPA is the ligand of this
receptor [42]. LPA1 and LPA2 are widely expressed in most tissues and interact with Gi/o, Gq/11, G12/13,
or Gs upon activation [43]. Activated G proteins recruit downstream secondary messengers, such as
MAP kinase, Akt, Rho, and PI3 kinase pathways, which promote cell proliferation and cell migration [2].
LPA3 couples with Gq/11 and Gi/o to regulate PLC activation and Ca2+ mobilization [43]. P2Y receptors
belong to purinergic receptor family, which is demonstrated as a key regulators in nervous system [44].
LPA4 is expressed specifically in the pancreas, ovaries, and thymus, where it raises intracellular Ca2+
and cAMP levels through activation of Gq/11 and G12/13 [45]. LPA5, which is expressed at low levels in
multiple tissues and is highly expressed in kidney, interacts with Gq/11 and G12/13 to increase intracellular
cAMP levels [46]. LPA6, which has been reported to participate in hair follicle development [47],
is the most recently defined member of the LPAR family. The specific functions of each receptor have
been elucidated in studies using LPA receptor gene-knockout mice. LPA1-deficient mice exhibited
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reduced suckling, which was attributed to olfactory defects, and developmental abnormalities in the
neurological system, whereas LPA2 knockout animals had no obvious phenotype [48]. In addition,
LPA3-knockout mice exhibited delayed uterine implantation, altered embryo spacing, and reduced
litter sizes [49]. No noticeable phenotype was associated with LPA4 deletion. However, embryonic
fibroblasts from LPA4-knockout mice displayed hypersensitivity to LPA-induced cell migration [50].
LPA5−/− mice showed no obvious phenotype [51], but recent results have suggested that LPA5 might
prevents cancer progression and disease development by inhibiting cell motility and migration [52].
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2.3. The Functions of LPA in Stem Cells
In recent years, accumulating studies have revealed the importance of LPA-LPAR signaling
in stem cell biology. ATX-LPA axis is reported to regulate the pluripotency of ESCs through the
activation of PLC/Ca2+ signaling and c-myc expression [18,20,32]. LPA receptors have been identified
in HSCs, vascular stem cells, bone marrow stromal cells (BMSCs), neurospheres from neural stem
cells (NSCs), and embryonic stem cells (ESCs) [53]. In addition, some studies have suggested a role
of LPA in mesenchymal stem cells (MSCs): the ATX-LPA axis has been shown to regulate migration
of MSCs [54,55] and hair follicle morphogenesis [56] through LPA1–3 signaling. Moreover, LPA has
been reported to stimulate osteoblastic differentiation in TERT-overexpressing human MSCs through
interplay between LPA1 and LPA4 [57]. Furthermore, LPA promotes proliferation and migration
of adipose-derived MSCs via reactive oxygen species (ROS) and expression of ADAM12 [58,59].
On the other hand, lysophospholipids play important roles in neurogenesis and neural stem cell
(NSC) differentiation. LPARs have been identified on the surface of oligodendrocyte progenitor
cells [60,61] and hippocampus precursors [62,63]. In contrast, activation of LPA1/3 signaling inhibits
differentiation of neural progenitor cells derived from human ESCs [64]. Furthermore, it has been
reported that induced pluripotent stem cells (iPSC) express LPA1–4. Activation of LPA receptors and
stimulation of the downstream Rho/Rock pathway promotes differentiation and proliferation in these
cells [65]. Taken together, these findings suggest the involvement of the LP -LPARs axis in stem
cell differentiation, especially MSC and NSC development. However, the roles of LPA during the
hematopoietic process remain elusive.
Int. J. Mol. Sci. 2020, 21, 2015 5 of 17
3. Regulation of Hematopoiesis
3.1. Initiation of Hematopoiesis
Hematopoiesis is temporally and spatially controlled by numerous factors during embryonic
development in mice (Figure 3). Embryonic hematopoiesis takes place in several developmental
niches that are rapidly altered by environmental signals in accordance with the highly dynamic
conditions throughout embryonic development [66]. Before embryonic day (E) 10.5, blood islands in
the mesoderm of the extraembryonic yolk sac are the major site of blood cell generation [67]. During
this period, hemogenic angioblasts, which are bipotent precursors of endothelial and hematopoietic
cells, are the main source for primitive hematopoiesis [5]. Based on observations from in vivo single-cell
differentiation [68] and in vitro ESC culture, mesoderm cells have also been found to generate HE
to support definitive hematopoiesis in the yolk-sac [9]. In the later stage of murine embryonic
development (around E10.5), hematopoiesis transitions to the embryo proper, in organs such as the
aorta-gonad-mesonephros (AGMs) [69,70], placenta [71,72] and arteries [73]. In this stage, HSCs
emerge from HE through transcriptional regulation by RUNX1 [74,75]. At around E11.5 of embryonic
development, hematopoiesis migrates to the fetal liver, which is the major site of blood cell expansion
and maturation in the embryo [66]. Finally, at around E16.5, blood cell development transitions from
the fetal liver to the bone marrow where it forms colonies that form and maintain hematopoietic niches
throughout adult life [66].
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HSCs, which have the capability for self-renewal and long-term differentiation, are the source of
support for all types of blood ells throughout the tire ifespan of adult vertebrates. HSCs generate two
main cell lineages in vertebrates: the myeloid lineage (leukocyt s, erythrocytes, p atelets and dendritic
cells) nd the lymphoid lineage (T c lls, B cells and NK cells). Due to the short lifespan of these mature
bloo cells, the self-renewal ability of HSCs is critical [76]. In order to maintain blood meostasis,
it is necessary to continuously produc a huge quantity of progeny to replenish the depleti g pool
of ature blood cells. Following divisi n of an HSC in t e niche, the two daughter cells ca either
remain as stem cells or progress to differentiation. Th specialized process simultaneously m intains
the tem c ll pool size and produces an adequate number o mature blood cell in circulation [77].
The balance betwee self-renewal and differentiation thus needs to b tightly controlled. HSCs have
extensive linical utility du to their specialized characteristics and functions, particularly with regard
t s em cell transpl ntation. Th refore, investigating the mechan sms underlying HSC differe tiation
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is important for efficient clinical application of HSCs. In this study, we review the two main factors that
affect HSC differentiation and physiology: microenvironments and transcriptional factor networks.
3.2. Microenvironmental Factors
The physiological functions of HSCs are tightly controlled by complex structures in the bone
marrow microenvironment. Such structures are called the “niche”, which was first defined by Schofield
in 1978 [78]. Niche cells provide fundamental support for HSCs to regulate their quiescence, self-renewal
and differentiation [79]. Disruption of niche-derived signals causes severe defects in HSC development.
For example, ablation of osteoblast inhibited the expression of IL-7 and SDF-1, which are necessary for
B-cell development [80,81]. In the bone marrow microenvironment, stromal cells are crucial in the
regulation of HSC differentiation. They support HSC homeostasis by way of three functionalities [82].
First, stromal cells provide a suitable microenvironment for HSC differentiation. Furthermore, the
extracellular matrix (ECM), which is secreted by stromal cells, supports the growth of HSCs in their
specific niches. ECM plays a vital role in stem cell niches, where it serves as a seedbed for various
cells in the environment, controlling and regulating pH, osmotic pressure, and providing mechanical
and biochemical factors [82]. Secondly, stromal cells secrete cytokines and growth factors [82]. These
paracrine factors drive HSCs toward different cell lineages. When co-cultured with stromal cells,
purified CD34+ HSCs showed significantly higher expansion under cytokine treatment [83]. Various
cytokines secreted by stromal cells (such as interleukin family [84], fibroblast growth factors [85],
thrombopoietin [86,87], and stem cell factor “SCF” [88]) are involved in the regulation of early and late
hematopoiesis. Upon activation of their receptors, downstream signaling leads to changes in gene
expression and commitment of an HSC towards specific lineages. Finally, cell-cell interactions between
stromal cells and HSCs also critically affect this differential regulation [89]. Basically, the niches in bone
marrow are classified into two categories: the perivascular niche and the endosteal niche.
3.2.1. Perivascular Niche
The bone marrow is a highly vascularized organ; it has numerous arteries and veins that enter
the tissue to create a complex structure. The vast majority of HSCs are located close to blood vessels
in this microenvironment [90]. The HSCs that arose from the HE during embryonic development
remain associated with blood vessels, suggesting a juxtacrine interaction between these cells [91].
In this niche, endothelial cells (ECs) play a critical role in regulating biological processes in HSCs.
They produce indispensable factors, such as SCF, Notch ligands, and CXCL12, that are responsible for
HSC self-renewal and differentiation [91]. Furthermore, the stromal cells that express leptin receptor
(LepR) and nestin are the major source of CXCL12 and SCF, which maintain HSC in the junction
between sinusoids and arteries [92,93]. On the other hand, neural components that associate with
arteries also provide signals for HSC homeostasis in the bone marrow. Sympathetic neurons release
norepinephrine to control CXCL12 production, which in turn affects HSC trafficking from bone marrow
to blood [94]. Moreover, megakaryocytes produce TGF-β and thrombopoietin (TPO) to restrict the
proliferation of HSCs [95,96]. This mechanism, in which HSCs are regulated by their own descendants,
suggests the existence of a feedback loop during hematopoiesis.
3.2.2. Endosteal Niche
Imaging studies and fractionation results have shown that HSC numbers are enriched and
associated with the endosteal (inner) surface of the bone marrow, supporting the concept of the
endosteal niche [97–99]. Bone-lining osteolineage cells secret HSC regulatory molecules, such as
embigin and angiogenin, to regulate the quiescence of HSCs [98,100]. Previous studies have shown
that constitutive expansion of osteoblasts leads to increased numbers of HSCs, which strongly suggests
the importance of osteoblasts in the endosteal niche [101]. In addition, osteocytes have been reported to
regulate the expansion of myeloid progenitors and G-SCF-induced mobilization of HSCs [102]. On the
other hand, some studies have suggested contrary roles of osteoclasts in HSC regulation, such as
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proliferation and mobilization of HSCs [89,103]. Macrophages are another type of HSC progeny cell
that regulates HSC function. Studies have suggested that macrophages that are enriched adjacent to
the bone surface, referred to as “osteomacs”, restrict HSCs around the endosteal niche by providing
CXCL12-dependent adhesion [89,104,105].
3.3. Transcriptional Factor Networks
Upon induction by extracellular signals, such as cytokines or cell-cell contact, intracellular signals
evoke the functions of transcription factors (TFs) to regulate gene expression, which is responsible
for determination of cell fate in HSCs. To date, hundreds of TFs involved in the regulation of
hematopoiesis have been identified, making it difficult to delineate their interactions. However,
the advancement of technologies in genome-wide research and computational science has given
rise to accurate network models. In this review, we describe some TF interactions that have been
well-recognized in hematopoiesis.
3.3.1. EKLF-FLI1 Interactions
Erythroid Krüppel-like factor (EKLF) and Friend leukemia integration 1 (FLI1) are two well-studied
TFs involved in the regulation of HSCs during terminal differentiation towards the myeloid
lineage. EKLF promotes erythropoiesis [106,107], whereas FLI1 activates gene expression during
megakaryopoiesis [108]. EKLF suppresses FLI1–dependent transcription of the GPIX gene during
megakaryopoiesis, and EKLF-dependent transcription of the β-globin gene is ablated in MEF cells
transfected with FLI1 [109]. Previous findings have also suggested that EKLF and FLI1 have physical
contact and suppress the activity of each other [109]. EKLF and FLI1 might also recruit cofactors,
such as GATA-1, while forming multiprotein complexes that selectively activate the promoters of either
erythrocytic or megakaryocytic genes [110].
3.3.2. GATA Switch
Discovery of a DNA sequence that commonly resides in the promoter region of globin provided
the evidences for the identification of GATA motif (WGATAR). This observation led to the identification
of the protein family binding to this sequence: the GATA family of transcription factors [111,112].
GATA-1, -2, and -3 are classified as hematopoietic GATA factors based on their important activities
during HSC differentiation [113], whereas GATA-4, -5, and -6 play critical roles in cardiac function
and lung tissue [114]. GATA-1 is preferentially expressed in erythroid or megakaryocytic progenitors,
while GATA-2 is abundantly expressed in HSCs and myeloid progenitors [112,113,115]. During
hematopoiesis, the balance between the expression of GATA-1 and GATA-2 acts as a developmental
driver to promote myeloid differentiation [116]. In progenitor cells, GATA-2 positively regulates
its own expression by directly binding to the promoter region of the GATA-2 and p38/ERK/CXCL2
circuits [117,118]. Chromatin immunoprecipitation (ChIP) has shown that GATA-2 occupies the
promoter region of GATA-1. Upon stimulation by cytokines required for myeloid differentiation,
release of TAL and LSD1 from the promoter of GATA-1 leads to the expression of GATA-1 [119].
Furthermore, ChIP analysis has indicated that GATA-1 binds to the upstream region of the -70-kb
GATA-2 promoter domain, and thus represses the expression of GATA-2 with FOG-1 occupancy [120].
This “GATA switch model”, in which GATA-1 displaces GATA-2 during HSC differentiation, induces a
subset of transcription output and leads to lineage commitment [121].
3.3.3. PU.1/GATA-1 Antagonism
The interaction between PU.1 and GATA1 is an another example of the determination of lineage
commitment by TFs. PU.1 is responsible for monocytic differentiation in the myeloid lineage,
while GATA-1 induces erythropoiesis and megakaryopoiesis [122]. Furthermore, multiple lines of
evidence have indicated that GATA-1 reduces the effects of PU.1 by interacting with its regulatory
regions to suppress its expression [123,124]. Mathematical modeling has shown that this mutual
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repression also inhibits the opposing cis-transactivators or downstream target genes, further results in
lineage commitment [125].
4. Microenvironmental and Intracellular Effects of LPA during Hematopoiesis
Hematopoiesis is tightly controlled by the microenvironment surrounding HSCs. As previously
described, cytokines, ECM, and stromal cells play major roles in their niche. Since the bone marrow
is the main hematopoietic organ in adult humans, we here review the functions of LPA in bone
marrow. Recent studies have indicated that autotaxin and lipid phosphate phosphatases 2A (PPAP2A,
the enzyme that degrades LPA) are differentially expressed in bone marrow [21], suggesting the
presence of LPA. In recent years, an increasing number of studies have supported the concept that LPA
“indirectly” affects hematopoiesis by participating in the regulation of osteogenesis and stromal cell
activity. LPA has been reported to regulate osteogenesis by promoting the survival and proliferation
of osteoblasts [126,127]. Furthermore, the MLO-Y4 osteolineage cell responds to LPA by triggering
dendrite outgrowth [128]. Moreover, blockade of LPA1 signaling reduced the number of newly formed
osteoclasts [129]. On the other hand, Kanehira et al. showed that pharmacological activation of LPA1
delays culture-dependent senescence of human marrow stromal cells [130]. In addition, the LPA-LPA4
axis regulates hematopoiesis indirectly by affecting stromal cell activity to support hematopoiesis
in the bone marrow [131]. Since osteolineage cells have been reported to regulate the mobility and
activity of HSCs [98,100], these lines of evidence suggest the importance of the LPA-LPAR axis in the
regulation of hematopoiesis.
LPA and its analogue, S1P, have been suggested to stimulate proliferation and mobility of CD34+
HSCs [30,132–134]. S1P and LPA were also reported to promote the ability of primitive hematopoietic
cells to invade into the stromal cell layer [135]. During early development, the ATX-LPA axis has
been reported to participate in the regulation of hemangioblast differentiation through activation of
LPA1-induced phosphoinositide 3-kinase/Akt and Smad signaling [136]. These results support the
“direct” regulation of LPA during early hematopoiesis in the embryo. On the other hand, there is
increasing evidence to suggest that LPA mediates HSC lineage commitment, especially towards the
myeloid lineage but not the lymphoid lineage [17]. Moreover, gene profiling results have confirmed
the expression of LPARs in myeloid progenitors [21]. LPA1 is also involved in NM23-dependent
myeloid differentiation of leukemia cells [137]. On the other hand, LPA activates the Akt-mTor-PPARγ
signaling axis to convert monocytes into macrophages [31]. Taken together, these results suggest novel
and critical roles of LPA signaling during early hematopoiesis in the embryo and HSC differentiation
in the adult. Nevertheless, the roles of LPA and LPA receptor in terminal differentiation, such as
erythropoiesis and megakaryopoiesis, have not yet been fully confirmed.
Our laboratory investigated the functional roles of LPA in myeloid differentiation of HSCs.
We found that knockdown of LPA3 in zebrafish embryos led to severe erythrocyte defects [23],
suggesting that this particular LPA receptor is required for red blood cell (RBC) development during
early hematopoiesis. Our results also suggested that the LPA-LPA3 axis is involved in erythropoietin
(EPO)-dependent erythropoiesis and nuclear translocation of β-catenin. In addition, the effects of
LPA on erythropoiesis were diminished by blocking c-Jun activated kinase and PI3K/AKT, which are
the downstream signals of EPO receptor. These results suggested that LPA might have a synergistic
role with EPO in the regulation of erythropoiesis [23]. We further reported that activation of LPA2
and LPA3 oppositely regulated erythropoiesis [22]. In that study, we demonstrated Stimulation via
LPA2 and LPA3 agonist exerts antagonizing effects on erythropoiesis in both K562 cells and CD34+
HSCs. Furthermore, exposure to LPA3 agonist 2S-OMPT rescued the erythropoietic defect caused
by zLPAR3 morpholino oligonucleotide injection in zebrafish. Treatment of embryos with LPA2
agonist GRI977143 (GRI) resulted in an increased percentage of embryos with severe RBC defects.
Finally, our results showed that the RBC count, hemoglobin (HGB), and hematocrit (HCT) decreased
significantly after GRI injection, and conversely increased after 2S-OMPT treatment in BALB/c mice.
Overall, our results suggest that agents similar to GRI and 2S-OMPT could serve as powerful drug
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candidates to regulate erythropoiesis. We also demonstrated the inhibitory role of LPA2 during
RBC differentiation. Our group also found that LPA3 affects differentiation in megakaryopoiesis [25].
Notably, these results from pharmacological activators and shRNA experiments have demonstrated the
negative regulatory role of LPA3 during megakaryocyte differentiation in CD34+ HSCs. Furthermore,
morpholino-mediated blockage of LPA3 translation led to increased numbers of CD41-GFP+ cells in
Tg(CD41:eGFP) zebrafish. Taken together, our results suggest that the balance between the expression
levels of LPA2 and LPA3 might be a molecular switch for cell fate determination in the myeloid lineage
(Table 1).
Table 1. Microenvironmental and intracellular effects of LPA-LPAR axis during hematopoiesis.
BM MSCs: bone marrow mesenchymal stem cells; HSPC: hematopoietic stem and progenitor cells;
MEPs: megakaryocyte-erythroid progenitors.
Cell Type LPA-Related Effects Reference
Extracellular/
Indirect effects
BM MSCs Detectable level of ATX expression [21]
BM MSCs Activation of LPA1 retards cell senescence [129]
Endosteal osteoblasts High PPAP2A expression level [21]
Endosteal osteoblasts LPA promotes survival and proliferation [121,126]
MLO-Y4 cell line LPA triggers dendrite outgrowth [127]
BM PDGFRα+ cells LPA4 promotes the production of HSPC proliferationfactors [130]
Intracellular/
Direct regulation
THS119 cell line LPA-LPA1 axis promotes invasion ability [134]
Hemangioblasts LPA1 activates hematopoietic differentiation [135]
Leukemic cell lines LPA1 is involved in NM23-dependent myeloiddifferentiation [136]
Monocytes Activation of LPA-Akt-mTor-PPARγ signaling convertsmonocytes into macrophages [31]
CD34+ HSPCs LPA promotes the early stage of myeloid differentiation [21]
MEPs, K562 cell line Activation of LPA3 promotes erythrocyte differentiation [23,137]
MEPs LPA-LPA3 axis inhibits megakaryocyte differentiation [25]
MEPs, K562 cell line LPA2 inhibits both erythropoiesis and megakaryopoiesis [24,137]
5. LPA Receptor Agonists and Antagonists as Potential Treatments for Anemia
Anemia is a disease featuring a decline in the numbers of RBCs and a reduction of HGB or
HCT below normal range. A variety of medications have been developed to treat this disease. To
date, EPO is the most popular medicine to treat anemia caused by chronic kidney disease (CDK),
cancer, or AIDS. For example, Epogen, the most popular medication, has been developed for over 28
years for clinical use in patients with anemia [138]. The main component of Epogen is recombinant
erythropoietin (Epotein-alfa), which is produced in Chinese hamster ovary (CHO) cells. Recent studies
have focused on biosimilars of erythropoietin. Last April, Pfizer’s biosimilar medicine Retacrit was
approved by the US-FDA. Related products, such as Recormon (Epotein-beta) [139] and Aranesp
(darbepoetin alfa) [140] are commonly used for patients with anemia. However, recent studies have
reported that overdose of EPO treatment may cause many side effects, including cardiovascular
disease and tumorigenesis [141]. On the other hand, EPO is a protein pharmaceutical. Its high cost
of production may constitute a substantial burden for health insurance agencies in many countries.
Therefore, it is extremely urgent to development a new medication, preferably small-molecule drugs,
to replace EPO. Inhibitors of the hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) enzyme are
a new class of agents for the treatment of anemia [142]. HIF is hydroxylated by HIF-PH to cause its
degradation [143]. On the other hand, HIF is reported to play important roles in cell-cycle regulation
of HSC and production of EPO. Therefore, prevention of HIF degradation by HIF-PH inhibitors might
be a novel target for anemia treatment [144].Vadadustat (Akebia Therapeutics, Cambridge, MA, USA),
Roxadustat (FibroGen, San Francisco, CA, USA) and Daprodustat (GlaxoSmithKline, London, UK) are
recently developed HIF-PH inhibitors currently undergoing clinical trials [144,145].
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Most of the LPA agonists and antagonists are currently being tested in preclinical trials for
therapeutics for cancer or idiopathic pulmonary fibrosis [146]. We were the first group to show that
the activation of LPA3 by its agonist, 2S-OMPT, strongly increased the numbers of RBCs in zebrafish
embryos and adult mice. Furthermore, our unpublished results show that LPA3 agonists hold potential
as therapeutics for anemia. We used phenylhydrazine to induce hemolytic anemia in a mouse model.
Administration of 2S-OMPT not only rescued the reduction in erythrocytes, but also the HGB and HCT
levels in the peripheral blood. It also increased the athletic ability of mice, as analyzed by voluntary
wheel running. We suggest that a new LPA3 agonist should be developed as a potential treatment for
anemia, since such a small-molecule agent would have lower cost and higher specificity for its target.
6. Conclusions
The hematological roles of LPA is increasingly apparent during blood cell development and
disease. Previous investigations have implied that LPA plays key roles in the regulation of early stage
of progenitor cells through their support of the precise regulation of HSC niches. Our results led to
an important conclusion: LPA not only affects immature precursors, but also provides crucial signals
during the terminal stages of myeloid lineage specification. Moreover, given that myeloid progenitors
express LPA receptors in different patterns and combinations, it is likely that their effects are precisely
balanced with the regulation of stem cell fates. Since LPA3 agonists have momentous effects on RBC
numbers and behavior in mice, our studies may provide a new therapeutic strategy for anemia.
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